@article{oai:tohoku-mpu.repo.nii.ac.jp:00000737,
 author = {佐久間, 若菜 and Sakuma, Wakana and 宇野, 尭 and Uno, Takashi and 岡田, 浩司 and Okada, Kouji and 藤盛, 寿一 and Fujimori, Juichi and 薄井, 健介 and Usui, Kensuke and 大河原, 雄一 and Ohgawara, Yuichi and 渡辺, 善照 and Watanabe, Yoshiteru},
 issue = {64},
 journal = {東北医科薬科大学研究誌, Journal of Tohoku Medical and Pharmaceutical University},
 month = {Dec},
 note = {In this case, we added NMDA antagonist memantine hydrochloride to cholinesterase inhibitor rivastigmine as the off-label use to further improve the cognitive function of a patient with severe Lewy body dementia. although the treatment period with the medicine was as short as 10 days, improvements in cognitive function and physical function were clearly confirmed by mental state（NM scale）and activities of daily living（N-ADL）but not Mini Mental State Examination（MMSE）which is usually used. And after discontinuing administration of the medicine because of the development of liver dysfunction, these improvements gradually disappeared. Based on these results, it was shown that the effect of memantine hydrochloride on symptoms of patients with Lewy body dementia may be observed even in a short period of administration, and that it is important for the pharmacists in the medical field to properly evaluate the effects of medicine using not only the usual cognitive function test but also other ones depending on the patient s pathophysiological situation.},
 pages = {83--90},
 title = {重症レビー小体型認知症においてメマンチンの短期間投与で有効性が示唆された1 例 ～適切な認知機能検査選択の重要性と薬剤師における今後の課題～},
 year = {2017},
 yomi = {サクマ, ワカナ and ウノ, タカシ and オカダ, コウジ and フジモリ, ジュイチ and ウスイ, ケンスケ and オオカワラ, ユウイチ and ワタナベ, ヨシテル}
}